The investigation centered on comparing two genetically defined cancer cell cultures derived from models of NSCLC: the ATF4-high KP-O and the ATF4-low KP-Y populations. Initial drug screening revealed a surprising specificity in their metabolic dependencies. While both were unresponsive to inhibitors targeting various amino acid transporters and metabolic enzymes such as SLC7A11, BCAT, or PHGDH, KP-O cultures exhibited heightened sensitivity to glutamine deprivation and treatment with DON, a glutamine analogue toxic to cancer cells. This disparity underscores the pivotal role of glutamine metabolism in determining therapeutic responses.

Delving deeper, the focus shifted towards targeting glutaminolysis—the conversion of glutamine to glutamate—central to cellular bioenergetics and biosynthesis. The study employed glutaminase inhibitors (GLSi) CB-839 (telaglenastat) and BPTES, agents capable of halting this rate-limiting step. Remarkably, KP-O cells demonstrated pronounced sensitivity to both drugs, linking high ATF4 expression and glutaminolysis dependency. Additionally, antagonism of ASCT2, the principal glutamine transporter using V-9302, mirrored this effect, further accentuating glutamine’s indispensable role in sustaining KP-O cell viability.

Mechanistic exploration through metabolic rescue experiments painted a nuanced picture of glutamate’s centrality. Pretreatment of KP-O cultures with dimethyl-2-oxoglutarate (DMG), a cell-permeable α-ketoglutarate analog that replenishes critical TCA cycle intermediates, or pyruvate derived from glucose metabolism, effectively reversed sensitivity to CB-839. This rescue was unique as other tested metabolites or antioxidants failed to confer protection, except for erastin, a cysteine–glutamate antiporter system inhibitor. These findings emphatically pinpointed glutamate exhaustion rather than downstream metabolic disruptions as the culprit for GLSi-induced cytotoxicity in KP-O cultures.

Critical to the narrative is the integral role played by ATF4. Genetic ablation or pharmacological attenuation of ATF4 activity using ISRIB (Integrated Stress Response Inhibitor) rendered KP-O cells resistant to CB-839, underscoring the dependency of glutaminase sensitivity on this transcription factor. Conversely, forced ATF4 overexpression in the historically resistant KP-Y cultures conferred newfound vulnerability to GLS inhibition, demonstrating a causal relationship. This interplay also extended to 3D tumor spheroid models: KP-O spheroids lost their characteristic anoikis resistance—a hallmark of metastatic potential—upon GLSi or V-9302 treatment, a defect that was likewise reversed when ATF4 was inhibited.

From a translational perspective, in vivo experiments confirmed the therapeutic promise of targeting glutaminolysis within the metastatic microenvironment. Intravenous transplantation of KP-O cultures into murine hosts resulted in aggressive lung metastasis under vehicle treatment but was nearly abolished with CB-839 administration. Strikingly, KP-Y cells implanted similarly evoked minimal metastatic burden regardless of treatment, demonstrating specificity. Notably, CB-839 did not impede the primary tumor growth in either model following subcutaneous transplantation, a divergence highlighting the metastasis-focused effectiveness of GLS inhibition.

Quantitative assessments endorsed these observations, with CB-839 treatment virtually eradicating distant metastases from KP-O tumors without affecting their primary mass or growth kinetics. This selective suppression of metastatic seeding or outgrowth, sparing tumor proliferation, suggests a unique dependency of metastatic cells on glutaminolysis mediated by ageing and ATF4 activation. These insights may explain the clinical challenges in treating metastasis and underscore the need for tailored metabolic interventions targeting this axis.

This study pioneers the conceptual junction where ageing biology intersects with cancer metabolism and metastasis. The integrated stress response, governed by ATF4, commandeers metabolic rewiring that fosters metastatic competence through glutamine and glutamate utilization. By exploiting this axis using clinically relevant GLS inhibitors, such as CB-839, there appears to be a viable strategy to thwart metastasis specifically in cancers with elevated ATF4 signaling—a phenotype enriched in aged patients.

Future clinical translation of these findings could revolutionize NSCLC management in older demographics, where current therapies exhibit limited efficacy against metastatic disease. It reveals how stress-adaptive transcription factors reshape metabolic landscapes within tumors, creating transient but exploitable vulnerabilities. Moreover, it invites broader applications across cancers exhibiting stress response hyperactivation, potentially heralding a new class of metabolically targeted anti-metastatic agents.

In summary, the novel identification of ageing-induced ATF4-dependent glutamine addiction in metastatic NSCLC cells presents a compelling target for intervention. GLS inhibitors, currently progressing through clinical trials, may find renewed focus as adjuvants to prevent metastatic progression rather than solely tumor reduction. This paradigm shift champions metabolic stress signaling as the Achilles’ heel of metastatic dissemination, reshaping therapeutic paradigms in oncology.

The study’s rigorous integration of cellular, molecular, and in vivo models highlights the precision with which cancer metabolism can be therapeutically manipulated. The metabolic plasticity modulated by ATF4 not only sustains metastasis but unveils a highly selective, context-dependent vulnerability. In doing so, it sets a precedent for unraveling complex age-related oncogenic programs through metabolic intervention, promising enhanced survivorship and quality of life for patients burdened by aggressive lung cancers.

As this research lays the groundwork for targeted metabolic therapies, it also prompts vital questions about long-term effects, resistance mechanisms, and patient stratification. The intersection of ageing biology with cancer therapeutics will undoubtedly continue to burgeon, catalyzing innovative strategies that are as complex and adaptive as the disease they aim to conquer.

Subject of Research: Metabolic rewiring driven by ATF4 in ageing and its impact on metastasis in non-small cell lung cancer.

Article Title: Ageing promotes metastasis via activation of the integrated stress response.

Article References:
Patel, A.A.H., Dzanan, J.J., Ali, K.X. et al. Ageing promotes metastasis via activation of the integrated stress response. Nature (2026). https://doi.org/10.1038/s41586-026-10216-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10216-0

The study begins with a fundamental biological question: how do polyamines mediate their contrasting effects on healthy and malignant cells? Prior research has established that polyamines facilitate autophagy—a process that removes defective organelles and proteins—through activation of the isoform eIF5A1. This protein is indispensable for mitochondrial respiration and cellular health in normal tissues. However, cancer cells display a profound metabolic shift known as the Warburg effect, favoring aerobic glycolysis to fuel rapid proliferation. The current work addresses whether polyamines play a contributory role in orchestrating this metabolic reprogramming and, if so, through what molecular intermediaries.

Employing state-of-the-art proteomic methodologies, Dr. Higashi’s team analyzed over 6,700 proteins in human cancer cell lines after manipulating intracellular polyamine concentrations. By pharmacologically depleting polyamines and then reintroducing spermidine, the researchers could precisely dissect the impact of these molecules on protein synthesis and metabolic pathways. Intriguingly, instead of enhancing mitochondrial respiration as seen in healthy cells, polyamines predominantly stimulated glycolysis-related proteins in cancer cells. This observation shifts paradigms, signifying that polyamines actively rewire energy metabolism to support malignant growth.

Central to these findings is the differential regulation of two highly homologous proteins: eIF5A1 and eIF5A2. Despite sharing 84% amino acid sequence similarity, their functional distinctions are profound. While eIF5A1 activation aligns with beneficial autophagic pathways, eIF5A2 is upregulated specifically in cancer cells. Elevated eIF5A2 expression was tightly correlated with increased synthesis of ribosomal proteins such as RPS27A, RPL36AL, and RPL22L1, which have known oncogenic associations. This selective translation regulation hints at a cancer-specific program driven by polyamine-mediated eIF5A2 that promotes tumor progression.

Delving deeper, the study elucidated the regulatory circuit controlling eIF5A2 production. Normally, a microRNA molecule known as miR-6514-5p suppresses eIF5A2 translation, thereby maintaining low baseline levels of the protein in non-cancerous cells. However, polyamines disrupt this suppression, effectively lifting the translational blockade and enabling increased eIF5A2 synthesis. This novel mechanism provides a direct link between metabolic status, translational control, and oncogenic potential. It exemplifies how subtle RNA-mediated checkpoints can be subverted in pathological contexts.

The ramifications of these findings are profound for both therapeutic development and the broader understanding of aging biology. Polyamine supplementation has been widely touted for its anti-aging properties, given its ability to stimulate mitochondrial autophagy and enhance cellular resilience. Nonetheless, these new insights warn against indiscriminate use of polyamine boosters, as tissues harboring early precancerous changes might inadvertently fuel malignancy via the eIF5A2 axis. Therapeutic strategies will need to finely balance these opposing actions to harness polyamines’ benefits without triggering oncogenesis.

Importantly, the research paves the way for novel targeted cancer therapies. By focusing on the protein synthesis machinery specific to cancer cells—namely, eIF5A2 and its interactions with ribosomal components—drug designers may develop inhibitors that selectively block tumor growth while sparing normal tissues. This cancer-selective vulnerability holds promise for higher efficacy and lower side effects compared to conventional cytotoxic treatments, which broadly impact dividing cells.

Moreover, this study underscores the critical significance of context-dependent molecular activities. The dichotomy between eIF5A1 and eIF5A2 exemplifies how paralogous proteins can attain vastly distinct biological roles through differential regulation, interaction networks, and cellular localization. Polyamines serve as metabolic signals that tip the balance between these isoforms, configuring a gene expression landscape compatible either with cellular longevity or malignant transformation.

The methodological rigor of the research deserves mention. The team’s use of quantitative proteomics to capture thousands of protein expression changes provides a systems-level view seldom achieved in cellular metabolism studies. Through integrated molecular biology techniques, including RNA interference and microRNA manipulation, they established causal relationships rather than mere correlations. Such comprehensive approaches elevate our mechanistic comprehension and open new investigative avenues into translational control in cancer.

In summary, the findings reported by Associate Professor Kyohei Higashi and colleagues represent a major advance in deciphering the dualistic roles of polyamines in human health and disease. By revealing that polyamines promote cancer cell proliferation via upregulation of eIF5A2 and associated ribosomal proteins—mechanistically distinct from the beneficial autophagic activation prompted by eIF5A1—this work resolves a longstanding biological paradox. The identification of miR-6514-5p as a key regulatory node further enriches our molecular understanding and supplies a promising therapeutic target for oncological intervention.

As research continues to unravel the intricate molecular interplay governing aging and cancer, this study highlights the necessity of precisely defining biochemical context before clinical applications. Polyamines, long admired as anti-aging compounds, must now be approached with careful scrutiny to avoid unintended oncogenic risk. Meanwhile, the selective vulnerability of eIF5A2-dependent translation in tumors offers a beacon of hope for next-generation cancer pharmaceuticals designed to outmaneuver malignancy at its metabolic core.

Subject of Research: Cells

Article Title: Polyamines stimulate the protein synthesis of the initiation factor eIF5A2 participating in mRNA decoding distinct from eIF5A1

News Publication Date: 1-Aug-2025

Web References:
Journal of Biological Chemistry Article
DOI: 10.1016/j.jbc.2025.110453

References:
Higashi K, et al. Polyamines stimulate the protein synthesis of the initiation factor eIF5A2 participating in mRNA decoding distinct from eIF5A1. Journal of Biological Chemistry. 2025 Aug 1;301(8).

Image Credits:
Dr. Kyohei Higashi, Tokyo University of Science, Japan

Keywords

Biochemistry, Molecular chemistry, Molecules, Physiology, Senescence, Cellular senescence, Human health, Clinical research, Cancer research, Molecular biology, Biomolecules